Catalog No.
YHE40101
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Arg24-Tyr145
Predicted molecular weight
16.62 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P43220
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone., PMID:40515833
Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes., PMID:40514652
[Bariatric surgery versus GLP-1 and dual GIP/GLP-1 receptor agonists : Effects on weight, risk factors and prognosis]., PMID:40514456
The management of hypothalamic obesity in craniopharyngioma., PMID:40514321
Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease: A Retrospective Cohort Study Using TriNetX., PMID:40513888
Designing structure-specific and switchable allosteric effectors for GPCRs based on the causality and energetics of inherent signaling., PMID:40513649
High-dimensional Iterative Causal Forest (hdiCF) for Subgroup Identification Using Health Care Claims Data., PMID:40512658
Exploring the role of glucagon-like peptide-1 receptor agonists in critical illness: mechanisms, benefits, and clinical implications., PMID:40512576
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes., PMID:40512543
Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies., PMID:40512404
Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting., PMID:40510690
Efficacy and safety of finerenone in obesity-related glomerulopathy., PMID:40510688
GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy., PMID:40510546
Oral semaglutide for the treatment of obesity: a retrospective real-world study., PMID:40510489
Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis., PMID:40509955
GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives., PMID:40508146
Now and the Future: Medications Changing the Landscape of Cardiovascular Disease and Heart Failure Management., PMID:40507711
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs., PMID:40507574
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553
Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications., PMID:40507246
Complexity of Metabolic dysfunction-associated steatotic liver disease (MASLD): State of art review., PMID:40506815
Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence., PMID:40506769
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia., PMID:40506208
GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study., PMID:40505816
Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review., PMID:40505607
Hemorrhoid risk among people with diabetes mellitus using glucose lowering agents., PMID:40504374
Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry., PMID:40503712
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol., PMID:40502777
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes., PMID:40502555
The fasting and the furious: reconciling fasting guidelines with glucagon-like peptide-1 receptor agonists, 'Sip-til-Send' policies and gastric ultrasound., PMID:40502386
GLP-1 receptor agonist use in elective lumbar spine surgery: Reduced pseudarthrosis rates and favorable safety profile., PMID:40502373
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors., PMID:40501737
Choice of Insulin Coformulations: Biphasic Insulin Versus Insulin-GlP1RA., PMID:40500836
Glucagon-like peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: a Systematic Review and Meta-analysis., PMID:40499738
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide., PMID:40499315
Tirzepatide: a novel therapeutic approach for Alzheimer's disease., PMID:40498212
GLP-1RA and the possible skin aging., PMID:40498168
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353
Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials., PMID:40497333
Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release., PMID:40497273
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment., PMID:40497223
Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists., PMID:40496649
Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors., PMID:40496570
The potential biomarker value of soluble CD36 in the treatment of diabetic kidney disease: evidence from GLP-1 and insulin interventions., PMID:40496556
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction., PMID:40496391
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass., PMID:40495947
Therapeutic Effects of Finerenone and Exenatide on Diabetes-Induced Heart Failure: A Combined Approach Targeting Inflammation and Oxidative Stress., PMID:40494432
Navigating the clinical benefits, risks, and emerging controversies with glucagon-like peptide-1 receptor agonists., PMID:40493797
Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis., PMID:40493069
2025 ISOBS OBA emergency manual: new drugs, devices, diversions, and dysfunction., PMID:40492872
For research use only. Not for human or drug use.
